-
Preventing, Detecting, and Analyzing Data From Suspected Fraudulent Respondents in Online Surveys, with Examples From Health Preference Studies
Feb 17, 2023, 10:47 AM -
Digital Endpoint Adoption: the How, What and Why
Feb 10, 2023, 12:54 PM -
FDA Patient-Focused Drug Development (PFDD) Guidance - Part 1
Feb 7, 2023, 12:48 PM -
Achieving Fit for Purpose Data from Wearables for Age-Related Diseases
Jan 13, 2023, 15:25 PM -
Strategies and Skills to Land Your First Job: The Interview
Dec 13, 2022, 13:01 PM -
Looking Beyond Survival Data: Understanding the Value of Non-OS Endpoints in Oncology Reimbursement Decision-Making
Dec 6, 2022, 13:41 PM -
Different HTA Perspectives on Reliably Estimating Treatment Effects
Nov 16, 2022, 11:02 AM -
Actualización de Política de Salud: ISPOR América Latina
Nov 15, 2022, 09:46 AM -
Can the Benefits From Biosimilars Be Sustainably Increased? Policy Recommendations for Europe, Middle East and Canada
Oct 20, 2022, 10:44 AM -
Oportunidades de carrera en HEOR para América Latina | Career Opportunities in HEOR in Latin America
Oct 13, 2022, 18:21 PM -
Health Insurance in Africa: Sustainability in Focus
Oct 11, 2022, 10:03 AM -
Availability and Access to Innovative Therapies in Latin America
Oct 6, 2022, 19:11 PM -
Souring On SUCRAs: When Treatment Ranking Goes Wrong
Oct 6, 2022, 15:25 PM -
On the Validity of Statistical Analyses with Privacy-Preserving Synthetic Data
Sep 30, 2022, 16:50 PM -
Fit for Local Context? Establishing or Improving Deliberative Processes for HTA
Sep 30, 2022, 16:11 PM -
Network Meta-Analysis - Special Topics
Sep 22, 2022, 13:41 PM -
Clinical Outcome Assessments in the Asia Pacific Region: Strategy & Implementation
Sep 16, 2022, 09:47 AM -
How Can Society Sustainably Benefit From Biosimilars? Global Learnings and Policy Recommendations for Australia
Sep 15, 2022, 19:16 PM -
An Introduction to Network Meta-Analysis
Sep 8, 2022, 12:33 PM -
Differentiating Between Patient Preferences, Patient Reported Outcomes and Patient Engagement
Sep 8, 2022, 10:26 AM